Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results
ICosapent ethyl (IPE) added to statin therapy reduced initial CV events by 25% and total CV Events by 30% in the REDUCE-IT study. The study is the first to evaluate the effects of IPE on atherosclerotic plaque characteristics in a high-risk CV population with persistently high triglyceride levels.
